

3.1 患者背景一覽表

3.1.1 患者背景一覽

患者背景		血縁者間 骨髓移植	血縁者間末梢血 幹細胞移植	非血縁者間 骨髓移植	臍帯血移植	合計
患者数		2376	3005	5865	4646	15892
性別	男	1332 (56.1%)	1740 (57.9%)	3481 (59.4%)	2748 (59.2%)	9301 (58.5%)
	女	1044 (43.9%)	1265 (42.1%)	2384 (40.7%)	1898 (40.9%)	6591 (41.5%)
	不明・未記載	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
年齢	0-17	785 (33.0%)	276 (9.2%)	807 (13.8%)	813 (17.5%)	2681 (16.9%)
	18-55	1238 (52.1%)	1964 (65.4%)	3529 (60.2%)	2302 (49.6%)	9033 (56.8%)
	56-	353 (14.9%)	765 (25.5%)	1529 (26.1%)	1531 (33.0%)	4178 (26.3%)
	不明・未記載	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
診断	AML	736 (31.0%)	1205 (40.1%)	2229 (38.0%)	2077 (44.7%)	6247 (39.3%)
	ALL	605 (25.5%)	508 (16.9%)	1113 (19.0%)	816 (17.6%)	3042 (19.1%)
	ATL	69 (2.9%)	145 (4.8%)	309 (5.3%)	163 (3.5%)	686 (4.3%)
	CML	55 (2.3%)	69 (2.3%)	149 (2.5%)	120 (2.6%)	393 (2.5%)
	MDS	199 (8.4%)	232 (7.7%)	611 (10.4%)	423 (9.1%)	1465 (9.2%)
	NHL	192 (8.1%)	442 (14.7%)	609 (10.4%)	457 (9.8%)	1700 (10.7%)
	固形腫瘍	51 (2.2%)	45 (1.5%)	10 (0.2%)	101 (2.2%)	207 (1.3%)
	その他	469 (19.7%)	359 (12.0%)	835 (14.2%)	489 (10.5%)	2152 (13.5%)
移植時病期	CR	1129 (47.7%)	1182 (39.7%)	2946 (50.4%)	1747 (37.8%)	7004 (44.3%)
	Non-CR	820 (34.7%)	1627 (54.6%)	2368 (40.5%)	2528 (54.7%)	7343 (46.4%)
	その他	363 (15.3%)	119 (4.0%)	441 (7.5%)	266 (5.8%)	1189 (7.5%)
	不明・未記載	54 (2.3%)	53 (1.8%)	94 (1.6%)	84 (1.8%)	285 (1.8%)
BU剤型	BU (経静脈)を含むレジメン	515 (92.6%)	959 (87.1%)	1791 (89.6%)	1048 (92.2%)	4313 (90.0%)
	BU (経口)を含むレジメン	41 (7.4%)	142 (12.9%)	209 (10.5%)	89 (7.8%)	481 (10.0%)
前治療レジメン	BU (経静脈)+CY±other	206 (12.7%)	247 (12.4%)	562 (11.8%)	157 (4.2%)	1172 (9.7%)
	CY+TBI±other	830 (51.0%)	720 (36.1%)	2053 (43.0%)	1258 (33.7%)	4861 (40.1%)
	BU (経静脈)+FL±other	271 (16.7%)	661 (33.1%)	1184 (24.8%)	829 (22.2%)	2945 (24.3%)
	FL+TBI±other	321 (19.7%)	367 (18.4%)	973 (20.4%)	1493 (40.0%)	3154 (26.0%)
GVHD予防薬	MTX+CyA	1393 (58.6%)	1447 (48.2%)	952 (16.2%)	1166 (25.1%)	4958 (31.2%)
	MTX+FK506	643 (27.1%)	605 (20.1%)	4562 (77.8%)	1521 (32.7%)	7331 (46.1%)
	その他	340 (14.3%)	953 (31.7%)	351 (6.0%)	1959 (42.2%)	3603 (22.7%)

略語	
BU	Busulfan
CY	Cyclophosphamide
TBI	Total body irradiation
FL	Fludarabine phosphate
CI	Confidence interval
N	Number of cases observed